|
MechanismKRAS G12C inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
0 Patents (Medical) associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
100 Deals associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.
100 Translational Medicine associated with Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.